Prof. Arjan Griffioen on CimCure’s cancer vaccine approach to tumour blood vessels

How CimCure is developing vaccines designed to target the blood vessels that help tumours grow.

In this video, Prof. Arjan Griffioen, Founder and CSO of CimCure and Professor of Experimental Oncology at Amsterdam UMC, shares the story behind CimCure’s cancer vaccine technology. Built on years of research into angiogenesis and tumour vasculature, CimCure is developing vaccines designed to target the blood vessels that solid tumours depend on for oxygen, nutrients, and growth.

The company’s first clinical study is now underway in patients with bladder cancer, marking an important step in translating this scientific insight into a potential new treatment approach. In the interview, Arjan reflects on the road from academic discovery to company creation, the ambition to expand into other cancer indications, and the importance of building a pipeline of next-generation vaccines.

Catalyze has supported CimCure from the early stages of the company’s journey, working together on several successful grant applications to help advance new projects and strengthen the company’s development pipeline. This collaboration reflects what drives our work: helping ambitious life sciences innovators move promising science closer to patients.